FIG. 3.

Dose-response curves for inhibitors against WT and mutant pseudoviruses containing N, C, or NC resistance mutations. (A) Inhibition of the JR-CSF pseudoviruses with the N44* peptide. (B) Inhibition of the JR-CSF pseudoviruses with the C34 peptide. (C) Inhibition of the JR-CSF pseudoviruses with sCD4. (D) Inhibition of the HXB2 pseudoviruses with the N44* peptide. (E) Inhibition of the HXB2 pseudoviruses with the C34 peptide. (F) Inhibition of the HXB2 pseudoviruses with sCD4. Luciferase activity for each pseudovirus was normalized to its control culture without inhibitor. Results in panels A to C (JR-CSF pseudoviruses) are averages from all experiments. Results in panels D to F (HXB2 pseudoviruses) are representative graphs from at least five independent experiments.